Vertex Pharmaceuticals Incorporated (NDAQ:VRTX) was upgraded by JMP Securities from a “mkt perform” rating to a “mkt outperform” rating in a research report issued to clients and investors on Friday.

Separately, Citigroup Inc initiated coverage on Vertex Pharmaceuticals in a research report on Wednesday, March 1st. They set a “buy” rating and a $105.00 target price on the stock.

Vertex Pharmaceuticals (NDAQ:VRTX) opened at 91.31 on Friday. Vertex Pharmaceuticals has a 12-month low of $71.46 and a 12-month high of $103.73. The firm has a 50-day moving average of $89.12 and a 200 day moving average of $85.20. The company’s market capitalization is $22.68 billion.

Your IP Address:

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated is engaged in the business of discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company operates in pharmaceuticals segment. Its business is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.

Receive News & Ratings for Vertex Pharmaceuticals Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals Incorporated and related companies with Analyst Ratings Network's FREE daily email newsletter.